GMALL, NCT02881086 / 2013-003466-13: Optimization of Therapy in Adult Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment |
|
|
| Completed | 3 | 1000 | Europe | Rituximab, Nelarabine, PEG-Asparaginase, Cranial irradiation, Imatinib, Idarubicin, Dexamethasone, Cyclophosphamide, Fludarabine, Vincristine, Mercaptopurine, VP16, Daunorubicin (DNR), Methotrexate, Stem cell transplantation, Cytarabine, Vindesine, Adriamycin, Prednisolone | Goethe University | Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | 12/24 | 12/24 | | |
| Recruiting | 2 | 65 | Europe | Inotuzumab ozogamicin | Nicola Goekbuget, Pfizer Pharma GmbH | Precursor Cell Lymphoblastic Leukemia | 06/25 | 12/25 | | |
GMALL-BLIVEN, NCT05182385: Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) |
|
|
| Recruiting | 1/2 | 39 | Europe | Blinatumomab, blincyto, Venetoclax, Venclyxto | Goethe University, University Hospital Schleswig-Holstein | ALL, Recurrent, Adult | 06/25 | 12/25 | | |
GMALLregistry, NCT02872987: GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial |
|
|
| Recruiting | N/A | 10000 | Europe | | Goethe University | Acute Lymphoblastic Leukemia, Leukemia, Non-Hodgkin's Lymphoma | 12/25 | 12/30 | | |
